Silexion Therapeutics Reports Preclinical Data for SIL-204 in Combination with 1L Chemotherapies for Pancreatic Cancer
Shots:
- Silexion reported preclinical data of SIL-204 (siRNA agent) + 5-fluorouracil + irinotecan & SIL-204 + gemcitabine combinations in KRAS G12D mutated human pancreatic tumor cell lines
- The data demonstrated a reduction in cancer cell confluence in contrast to 1L CT agents alone, where SIL-204 + 5-fluorouracil + irinotecan achieved reduction after 3 days
- Silexion will start the toxicology studies for SIL-204 in the forthcoming mos. & advance it in P-II/III trials in H1’26 for locally advanced pancreatic cancer (LAPC), plus initiate preclinical studies in colorectal cancer models
Ref: Globenewswire | Image: Silexion Therapeutics
Related News:- Light Horse Therapeutics Partners with Novartis to Discover Therapies for Cancer Treatment
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
